» Articles » PMID: 28912784

Comparison of the Protective Efficacy of Neutralizing Epitopes of 2009 Pandemic H1N1 Influenza Hemagglutinin

Overview
Journal Front Immunol
Date 2017 Sep 16
PMID 28912784
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The 2009 H1N1 influenza (Pdm09) pandemic has been referred to as the first influenza pandemic of the twenty-first century. There is a marked difference in antigenicity between the pandemic H1N1 virus and past seasonal H1N1 viruses, which allowed the pandemic virus to spread rapidly in humans. Antibodies (Abs) against hemagglutinin (HA), especially neutralizing Abs against epitopes in the head of HA, play critical roles in defending the host against the virus. Some preexisting neutralizing Abs that recognize neutralizing epitopes of Pdm09 HA, thereby affording cross-protection, have been reported. To better understand the protective effects of epitopes in Pdm09 HA, we constructed a series of plasmid DNAs (DNA vaccines) by cloning various combinations of Pdm09 neutralizing epitopes into the HA backbone derived from A/PR/8/1934 (H1N1). We subsequently compared the protective immune responses induced by these various forms of HA in a mouse model. We found that the plasmid DNAs with epitope substitutions provided better protection against lethal virus challenge and induced higher strain-specific antibody titers, with epitope Sa being the most effective. Moreover, the combination of epitopes Sa and Sb provided almost complete protection in mice. These findings provide new insights into the protective efficacy of neutralizing epitopes of influenza HA.

Citing Articles

Cellular and Molecular Immunity to Influenza Viruses and Vaccines.

Kasten-Jolly J, Lawrence D Vaccines (Basel). 2024; 12(4).

PMID: 38675771 PMC: 11154265. DOI: 10.3390/vaccines12040389.


Differential mitochondrial proteomic analysis of A549 cells infected with avian influenza virus subtypes H5 and H9.

Yang Y, Zhang Y, Yang C, Fang F, Wang Y, Chang H Virol J. 2021; 18(1):39.

PMID: 33602268 PMC: 7891018. DOI: 10.1186/s12985-021-01512-4.


Influenza-infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem.

Clemens E, Angeletti D, Holbrook B, Kanekiyo M, Jorgensen M, Graham B JCI Insight. 2020; 5(5).

PMID: 32078584 PMC: 7141390. DOI: 10.1172/jci.insight.135449.


MiRNA Targeted NP Genome of Live Attenuated Influenza Vaccines Provide Cross-Protection against a Lethal Influenza Virus Infection.

Gao F, Yang T, Liu X, Xiong F, Luo J, Yi Y Vaccines (Basel). 2020; 8(1).

PMID: 32028575 PMC: 7158662. DOI: 10.3390/vaccines8010065.


Universal influenza vaccines: from viruses to nanoparticles.

Wang Y, Deng L, Kang S, Wang B Expert Rev Vaccines. 2018; 17(11):967-976.

PMID: 30365905 PMC: 6300164. DOI: 10.1080/14760584.2018.1541408.

References
1.
Caton A, Brownlee G, Yewdell J, GERHARD W . The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell. 1982; 31(2 Pt 1):417-27. DOI: 10.1016/0092-8674(82)90135-0. View

2.
Chiu C, Ellebedy A, Wrammert J, Ahmed R . B cell responses to influenza infection and vaccination. Curr Top Microbiol Immunol. 2014; 386:381-98. DOI: 10.1007/82_2014_425. View

3.
GERHARD W, Yewdell J, Frankel M, Webster R . Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature. 1981; 290(5808):713-7. DOI: 10.1038/290713a0. View

4.
Krammer F, Palese P . Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol. 2013; 3(5):521-30. PMC: 3804342. DOI: 10.1016/j.coviro.2013.07.007. View

5.
Xu R, Ekiert D, Krause J, Hai R, Crowe Jr J, Wilson I . Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. 2010; 328(5976):357-60. PMC: 2897825. DOI: 10.1126/science.1186430. View